Harvey vs. Legora: What $600M in Legal AI Tells Buyers to Watch

In March 2026, two legal AI vendors closed funding rounds within days of each other. Harvey AI raised $200M at an $11 billion valuation, co-led by GIC and Sequoia (harvey.ai). Legora raised a $550M Series D at $5.55 billion, led by Accel, roughly tripling the $1.8B valuation it carried in October 2025 (TechCrunch). That is more than $600M into two names inside one quarter.

Most comparison pages treat that money as trivia and then drop you into a feature grid. It is not trivia. Capital at this scale is the cleanest viability signal a procurement team gets in a category that is about to consolidate, and the multiples underneath the headlines tell you something a feature table never will. The question is not which platform wins. It is which one survives the next eighteen months, and which one fits the matters you actually run.

The funding ledger as a buyer signal

Software you buy for a five-year matter needs a vendor that exists in five years. In legal AI specifically, the failure mode is not bankruptcy from a bad product. It is the vendor that raises a seed round, runs a flashy pilot at your firm, then cannot convert pilots into enterprise contracts before the money runs out.

GC AI's field guide frames it plainly. Many early-stage legal AI vendors will fail to convert, and the result is a wave of acquisitions and shutdowns, with M&A velocity already at historic highs (Clio bought vLex for $1 billion in 2025) (gc.ai). That is the backdrop a buyer is signing into. The vendor you pick has to outlast a thinning field, not just win a bake-off this quarter.

Harvey and Legora are both on the survivor side of that line. Harvey has raised more than $1.2 billion total and reached an estimated $300M in annual recurring revenue by May 2026, up from $195M at the end of 2025 (Sacra). Legora crossed $100M ARR by April 2026, going from $1M to $100M in eighteen months (Legora).

Both have real revenue, marquee customers, and enough runway to outlast the shakeout. So the survival question, for these two, is answered. The funding tells you they are safe to underwrite, which means the decision moves off "will this vendor exist" and onto "which one fits."

Reading the multiples

The interesting tell is the gap between revenue and valuation. Harvey's roughly $300M ARR against an $11B valuation is about a 37x multiple. Legora's $100M ARR against $5.55B is about 55x. Neither number is sane by traditional SaaS standards. Investors are pricing growth velocity and category dominance, not current cash flow.

That gap is not abstract for a buyer, because the multiple is the pressure the vendor's own investors are applying to its pricing. A vendor carrying a 55x multiple has to keep growing into it, and the lever it controls is per-seat economics. The higher the multiple, the more a buyer should expect future price pressure at renewal, and the harder it is to assume today's quote holds for the length of a multi-year engagement.

For a buyer, the higher multiple on Legora reads as a bet on speed. Legora got from $1M to $100M ARR in eighteen months from its October 2024 platform launch (Legora); Harvey took roughly three years from founding to cross $100M (Sacra). The lower multiple on Harvey reads as the more proven book of business: 1,500+ customers in 60+ countries, 142,000+ lawyers on the platform, and adoption by half of the Am Law 100 (Sacra).

One is priced like the incumbent, the other like the insurgent. That framing matters when you decide which roadmap risk you want to inherit. The incumbent multiple says the growth is partly behind it and the footprint is settled; the insurgent multiple says you are buying into a trajectory that still has to deliver, with the renewal exposure that implies.

Harvey vs. Legora at a glance

Dimension	Harvey	Legora
March 2026 valuation	$11B ($200M round, GIC + Sequoia)	$5.55B ($550M Series D, Accel)
ARR	~$300M (May 2026 est.)	$100M (April 2026)
Approx. ARR multiple	~37x	~55x
Customers	1,500+ in 60+ countries	1,000+ across 50 markets
Origin / focus	US-focused, LexisNexis partnership	European-rooted, cross-border
Jurisdictions / language	Primarily US	Research across 12 jurisdictions, multilingual
Compliance set	SOC 2 Type II, ISO 27001, GDPR, CCPA	SOC 2 Type II, ISO 27001, ISO 42001, GDPR, HIPAA
Pricing	Contact sales, unpublished	~$3,000/user/yr, 10-seat min (~$30K floor)

Sources: harvey.ai, Sacra, TechCrunch, Legora, gc.ai, Spellbook.

The two platforms up close

Harvey

Start with the scale. 142,000+ lawyers run Harvey, and half the Am Law 100 has already adopted it (Sacra). That is the number that defines the platform: it is the broad legal AI tool built around US legal work through a LexisNexis partnership, and it is the safe board-level choice. Nobody gets second-guessed for picking the platform half their peers already run.

The depth is not just headcount. Harvey customers have built more than 25,000 custom agents on the platform, with named clients including Ashurst, Baker Donelson, Cuatrecasas, and GSK Stockmann (harvey.ai). A large firm can shape the agent ecosystem to its own workflows rather than accept an off-the-shelf form.

The honest limitation is two-sided. There is no published pricing as of June 2026 (gc.ai), so the contact-sales model means a long procurement cycle and a negotiated number you cannot benchmark in advance. And its center of gravity is US legal work, not multi-jurisdiction cross-border practice.

• What to watch for: the procurement timeline (contact-sales rounds can stretch a quarter), how the negotiated seat price compares once you finally have it, and whether your non-US matters are genuinely covered or just tolerated.

Pick Harvey if you are a large US or US-anchored firm, you want the platform with the deepest peer adoption and an agent ecosystem you can customize, and you have the procurement appetite for an enterprise contact-sales negotiation.

Legora

Start with the price tag, because Legora actually publishes one. Roughly $3,000 per user per year with a 10-seat minimum, so the floor is a knowable ~$30,000 (Spellbook). That transparency is rare in this category and lets you model the line item before the first sales call.

The product itself is built primarily on Claude LLMs and positioned for complex, cross-border cases rather than as a general-purpose assistant (TechCrunch). Headquartered in New York with offices in Stockholm, Bangalore, London, and Sydney, it serves 1,000+ customers across 50 markets, including White & Case, Linklaters, and Barclays (Legora).

Its strength is being built cross-border. Legora offers legal research across 12 jurisdictions with European and multilingual strengths and GDPR built into its foundation, and its compliance set adds ISO 42001 and HIPAA on top of SOC 2 Type II and ISO 27001 (gc.ai). The tabular review interface suits side-by-side analysis across document sets, which is the shape of a lot of cross-border diligence work.

The honest limitation is the flip side of that velocity. It is the younger book of business and carries the higher valuation multiple, so more of what you are buying is a bet on continued growth than a settled enterprise footprint. The 10-seat minimum also rules out the smallest teams.

• What to watch for: renewal pricing against that 55x multiple, whether the jurisdictions you need are among the 12 covered, and how the tabular interface holds up on your actual document sets rather than a curated demo.

Pick Legora if your work is European or genuinely cross-border, you need multilingual research and the stricter compliance certifications, and you want a published per-seat number you can model before the sales call.

When neither fits: the narrower alternatives

Both platforms ask for serious money. Legora's floor is ~$30,000 a year, and enterprise commitments to either can run far higher into the hundreds of thousands depending on seats and scope. If you cannot underwrite a commitment that starts near $30K and climbs from there, or your need is one workflow rather than a platform, the category has cheaper and narrower options that map onto specific jobs.

• Research and drafting, incumbent-backed: Casetext CoCounsel is now part of Thomson Reuters. Use it when you want a Big-Law-grade research and drafting assistant backed by an established vendor rather than a venture-stage roadmap.
• Full contract lifecycle: Ironclad is contract lifecycle management with embedded AI. Use it when your core need is the contract workflow itself, from intake through renewal, not litigation or research.
• Document and contract review at scale: Luminance handles AI contract review and analysis and publishes a starting price. Use it when you want the narrow tool that maps to Legora's tabular-review strength, not the full platform.
• Policy-based review on a budget: LawGeex reviews contracts against your legal policy. Use it when your team genuinely cannot justify a platform commitment and needs one focused, lower-ceiling job done well.

These do less than Harvey or Legora by design. That is the trade. A tool scoped to one job costs less and proves value faster than a platform you have to grow into, and it leaves the door open to graduate to a platform later once the use case is proven.

A decision framework

Three questions narrow this faster than any back-and-forth on features.

1. Is your work US-anchored or cross-border? If most of your matters live in US law, Harvey's LexisNexis-backed depth and peer adoption is the path of least resistance. If you routinely touch multiple jurisdictions or non-English documents, Legora's 12-jurisdiction, multilingual coverage is the structural fit, and no amount of Harvey customization closes that gap cleanly.

2. Can you live with contact-sales opacity? Harvey will not give you a number until you are in a sales cycle. If your procurement process needs a per-seat figure to model before it can move, Legora's published ~$3,000/user/year is a real advantage. If you have the appetite and the budget for an enterprise negotiation, the opacity is just friction, not a dealbreaker.

3. Are you buying a platform or a job? If you want one workflow handled now, skip both and scope a narrower tool against that specific job. If you want a foundation your firm builds on for years, the funding ledger says both Harvey and Legora will still be standing to support it, and the choice collapses back to questions one and two.

Run a 30-day side-by-side pilot on your three most common matter types before signing anything. Put Legora in because it will quote you a seat price up front, and either Harvey or one narrow alternative in as the contrast. Score the output on the work you actually bill, then sign the platform that won that bake-off, not the one with the bigger valuation in the headline.